Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab
Not Applicable
Recruiting
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000017947
- Lead Sponsor
- Department of Rheumatology, Saga University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who corresponds to a contraindication of tocilizumab
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission rate at 24 weeks. Change of serum IL-6 levels at 24 weeks and 52 weeks
- Secondary Outcome Measures
Name Time Method Remission rate at 12 weeks and 52 weeks